BioSpace News Archive

Biohaven Ltd. (NYSE: BHVN) launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases.

Positive Results from Pivotal Trial of Better Therapeutics’ Investigational BT-001 Prescription Digital Therapy for Type 2 Diabetes Published in Diabetes Care.

Cidara Therapeutics, Inc. announced receipt of an $11 million milestone payment from Mundipharma under the licensing agreement established between the two companies in September 2019.

Kane Biotech Inc. announces that it has received an additional $425,000 USD of funding for its DispersinB Hydrogel® related to its Medical Technology Enterprise Consortium Research Project Award which was granted in 2020 and funded by the U.S. Department of Defense.

Nemaura Medical, Inc. announces that CEO Dr. Faz Chowdhury will present a corporate overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference.

SyntheX, Inc., an emerging growth biotechnology company innovating next-generation functional drug discovery engines, announced a research collaboration and license agreement with Bristol Myers Squibb to discover, develop and commercialize novel small molecules using SyntheX’s ToRNeDO platform for protein degradation.

South Rampart Pharma, a clinical-stage life science company advancing innovative medications for the treatment of pain, announced the issuance of a composition of matter US patent No. 11,458,142 for its novel, non-opioid, and non-liver toxic treatments for pain.

Inhibrx, Inc. announced that, based on discussions with the U.S. Food and Drug Administration, there is potential to pursue an accelerated approval in the U.S. for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with emphysema due to alpha-1 antitrypsin deficiency using functional alpha-1 antitrypsin serum levels as the surrogate endpoint.

Esaote North America announces a multi-year contract with Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company, serving more than 50% of the nation’s acute care providers.

Aridis Pharmaceuticals, Inc. announced that patient enrollment is closed in the AR-301 Phase 3 clinical study.